PET Scanning of Iodine-124-3F9 as an Approach to Tumor Dosimetry During Treatment Planning for Radioimmunotherapy in a Child with Neuroblastoma

A patient with advanced neuroblastoma who had failed chemotherapy presented with a large abdominal mass and virtually total bone marrow replacement by tumor on repeated marrow biopsies. She was considered a candidate for a Phase I 131I-3F8 radioimmunotherapy trial, (MSKCC 89-141A). As a potential ai...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of nuclear medicine (1978) Vol. 33; no. 11; p. 2020
Main Authors Larson, Steven M, Pentlow, Keith S, Volkow, Nora D, Wolf, Alfred P, Finn, Ronald D, Lambrecht, Richard M, Graham, Martin C, Di Resta, Gene, Bendriem, Bernard, Daghighian, Farhad, Yeh, Samuel D.J, Wang, G.-J, Cheung, Nai-Kong V
Format Journal Article
LanguageEnglish
Published United States Soc Nuclear Med 01.11.1992
Subjects
Adrenal Gland Neoplasms - diagnostic imaging
Adrenal Gland Neoplasms - radiotherapy
Animals
Child, Preschool
Female
Humans
Iodine Radioisotopes - therapeutic use
Neuroblastoma - diagnostic imaging
Neuroblastoma - radiotherapy
Radiation Dosage
Radioimmunotherapy
Tomography, Emission-Computed
Online AccessGet full text

Cover

More Information
Summary:A patient with advanced neuroblastoma who had failed chemotherapy presented with a large abdominal mass and virtually total bone marrow replacement by tumor on repeated marrow biopsies. She was considered a candidate for a Phase I 131I-3F8 radioimmunotherapy trial, (MSKCC 89-141A). As a potential aid to treatment planning, a test dose of 124I-3F8 was injected and the patient was imaged over the 72 hr postinjection using two BGO based PET scanners of different designs. Time activity curves were obtained, and the cumulated activity concentration of radiolabeled 3F8 in tumor was determined. Based on MIRD, an estimated radiation absorbed dose for 131I-3F8 was 7.55 rad/mCi, in the most antibody avid lesions. Because of low uptake and unfavorable dosimetry in some bulky tumor sites, it was decided not to treat the patient with radiolabeled antibody. Positron emission tomography of 124I-labeled antibodies can be used to measure cumulated activity or residence time in tumor for more accurate estimates of radiation absorbed tumor dose from radioiodinated antibodies and can help guide management decisions in patients who are candidates for radioimmunotherapy.
ISSN:0161-5505
1535-5667